Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label study of ALPS12 in extensive-stage small cell lung cancer
jRCT2031250274Phase 1Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of RG6538 in small cell lung cancer (SCLC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of ALPS12, Pharmacokinetics of ALPS12 and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
RG6538
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031250274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250274.